Targeting Glycolytic Reprogramming in Cholangiocarcinoma: A Novel Approach for Metabolic Therapy
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Cholangiocarcinoma (CCA) is a deadly cancer. Targeting cancer cell glycolysis, a key metabolic process, shows promise for new therapies and identifying biomarkers for this challenging disease.
Area Of Science
- Oncology
- Cancer Metabolism
- Biochemistry
Background
- Cholangiocarcinoma (CCA) is an aggressive cancer with poor prognosis, often diagnosed late due to subtle early symptoms.
- Understanding CCA development mechanisms and identifying therapeutic targets are critical due to diagnostic challenges.
- Metabolic reprogramming, particularly altered glycolysis, is a recognized hallmark of cancer, including CCA.
Purpose Of The Study
- To review metabolic alterations and signaling pathways in CCA development.
- To explore the role of glycolysis in CCA pathogenesis.
- To identify potential therapeutic targets and biomarkers for CCA through bioinformatic analysis.
Main Methods
- Literature review of cancer metabolism and signaling pathways in CCA.
- Analysis of the relationship between CCA and glycolysis using bioinformatic approaches.
- Investigation of non-coding RNAs and protein modifications in regulating CCA glycolysis.
Main Results
- Glycolysis is a central metabolic pathway dysregulated in CCA.
- Multiple signaling pathways, key enzymes, ncRNAs, and protein modifications influence CCA glycolysis.
- Bioinformatic analysis identified potential CCA-glycolysis related targets.
Conclusions
- Targeting glycolysis presents a promising therapeutic strategy for cholangiocarcinoma.
- Further research into CCA metabolic reprogramming can provide a basis for novel therapeutic development.
- Identifying specific targets is crucial for improving CCA treatment outcomes.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...